Acromegaly is associated with increased cardiovascular morbidity and mortality. However, increased growth hormone (GH) and insulin-like growth factor (IGF)-I exert deleterious effects on multiple organs and tissues and, in a direct or an indirect fashion, effect non-cardiac complications as well. The current knowledge about acromegalic arthropathy and sleep apnea will be briefly summarized here.
The articular manifestations of acromegaly were first recognized in Pierre Marie's original description of this disease in 1886. It is, perhaps, symbolic that Marie's name is connected not only with acromegaly but also with Marie-Strumpell disease (ankylosing spondylitis).
Arthropathy affects many, if not most, patients with acromegaly. In one form or another, musculoskeletal complaints are a leading cause of morbidity and functional disability in acromegaly. Several studies provided detailed epidemiologic description of acromegalic arthropathy. In the largest series of that kind, Detenbeck et al. (1973) found that 62% of the 229 patients examined had at
Journal of Endocrinology is committed to supporting researchers in demonstrating the impact of their articles published in the journal.
The two types of article metrics we measure are (i) more traditional full-text views and pdf downloads, and (ii) Altmetric data, which shows the wider impact of articles in a range of non-traditional sources, such as social media.
More information is on the Reasons to publish page.
|Sept 2018 onwards||Past Year||Past 30 Days|
|Full Text Views||0||0||0|